Clinical Study
Conversion to Sirolimus Therapy in Kidney Transplant Recipients with New Onset Diabetes Mellitus after Transplantation
Table 1
Baseline characteristics of the study population.
| | | All
| NODAT−
| NODAT+
| P value |
| | Recipient | | | | | | Age | 48 ± 12 | 48 ± 6 | 51 ± 2 | 0.1 | | Male sex | 277 (63) | 255 (61) | 22 (76) | 0.1 | Polycystic kidney
disease | 85 (19) | 75 (18) | 8 (27) | 0.2 | | Body mass index | 27 ± 6 | 27 ± 3 | 28 ± 1 | 0.2 | | HCV seropositive | 27 (6) | 26 (6) | 1 (3) | 0.5 | | ABO groups | | | | | | A | 163 (37) | 148 (36) | 15 (52) | 0.5 | | B | 52 (12) | 50 (12) | 2 (7) | 0.4 | | AB | 13 (3) | 12 (3) | 1 (3) | 0.5 | | O | 208 (48) | 197 (48) | 11 (38) | 0.5 | Time on dialysis
(months) | 51 ± 52 | 52 ± 53 | 43 ± 46 | 0.07 | | Immunosuppression | | | | | | Tacrolimus | 304 | 22 (93) | 22 (7) | 0.1 | | Cyclosporine | 90 | 81 (93) | 7 (7) | 0.4 | | Sirolimus | 42 | 42 (100) | 0 | | Mycophenolate
mofetil | 400 | 371 (93) | 29 (7) | | | Steroids | 436 | 407 (94) | 29 (6) | | | Donor | | | | | | ABO group | | | | 0.4 | | Male sex | 230 (53) | 213 (52) | 17 (59) | 0.5 | | Age (>60 years) | 153 (35) | 145 (36) | 8 (28) | 0.4 | | PRA < 20% | 417 (96) | 388 (95) | 29 (100) | 0.3 |
|
|
